It Seems Ceapro Inc. Will Go Down. Have Another Big Decline

 It Seems Ceapro Inc. Will Go Down. Have Another Big Decline

The stock of Ceapro Inc. (CVE:CZO) is a huge mover today! About 169,394 shares traded hands. Ceapro Inc. (CVE:CZO) has risen 6.00% since November 1, 2016 and is uptrending. It has outperformed by 0.07% the S&P500.
The move comes after 6 months negative chart setup for the $91.50M company. It was reported on Dec, 1 by Barchart.com. We have $1.16 PT which if reached, will make CVE:CZO worth $6.41M less.

More important recent Ceapro Inc. (CVE:CZO) news were published by: Seekingalpha.com which released: “Ceapro: A Small, Profitable, Fast-Growing Biotechnology Company” on November 04, 2016, also Marketwired.com published article titled: “Ceapro Inc. Announces the Grand Opening of New Bio-processing Extraction Facility”, Marketwired.com published: “Crystal Research Associates, LLC Issues Executive Informational Overview on …” on November 14, 2016. More interesting news about Ceapro Inc. (CVE:CZO) was released by: Marketwired.com and their article: “Ceapro Inc. Provides 2015 Business Highlights and 2016 Business Outlook” with publication date: April 18, 2016.

Ceapro Inc. is a Canada-based growth-stage biotechnology company. The company has a market cap of $91.50 million. The Company’s primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human and animal health industries using technology, natural and renewable resources. It has a 11.03 P/E ratio. The Company’s products include a commercial line of natural active ingredients, including beta glucan, avenanthramides , oat powder, oat oil, oat peptides and lupin peptides, which are marketed to the personal care, cosmetic, medical and animal health industries, and Veterinary therapeutic products, including an oat shampoo, an ear cleanser and a dermal complex/conditioner, which are manufactured and marketed to veterinarians in Japan and Asia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment